Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention

Thomas Mercher* and Juerg Schwaller**

*INSERM U1170, Equipe Labellisée Ligue Contre le Cancer, Gustave Roussy Institute, Université Paris Diderot, Université Paris-Sud, Villejuif, France, **Department of Biomedicine, University Children’s Hospital Beider Basel (UKBB), University of Basel, Basel, Switzerland

This review aims to provide an overview of the current knowledge of the genetic lesions driving pediatric acute myeloid leukemia (AML), emerging biological concepts, and strategies for therapeutic intervention. Hereby, we focus on lesions that preferentially or exclusively occur in pediatric patients and molecular markers of aggressive disease with often poor outcome including fusion oncogenes that involve epigenetic regulators like KMT2A, NUP98, or CBFA2T3, respectively. Functional studies were able to demonstrate cooperation with signaling mutations leading to constitutive activation of FLT3 or the RAS signal transduction pathways. We discuss the issues faced to faithfully model pediatric acute leukemia in mice. Emerging experimental evidence suggests that the disease phenotype is dependent on the appropriate expression and activity of the driver fusion oncogenes during a particular window of opportunity during fetal development. We also highlight biochemical studies that deciphered some molecular mechanisms of malignant transformation by KMT2A, NUP98, and CBFA2T3 fusions, which, in some instances, allowed the development of small molecules with potent anti-leukemic activities in preclinical models (e.g., inhibitors of the KMT2A–MENIN interaction). Finally, we discuss other potential therapeutic strategies that not only target driver fusion-controlled signals but also interfere with the transformed cell state either by exploiting the primed apoptosis or vulnerable metabolic states or by increasing tumor cell recognition and elimination by the immune system.

Keywords: pediatric AML, genomic landscape, mouse models, fusion oncogene, therapeutic targeting, UKBB

GENOMIC LANDSCAPE OF PEDIATRIC AML
From Cytogenetics to Next-Generation Sequencing

Molecular hematology–oncology starting in the 1970s of the last century was heavily influenced by the pioneering work of Janet Rowley and others that used conventional cytogenetics followed by the upcoming recombinant DNA technology to show that, in addition to other structural lesions, balanced chromosomal translocations frequently lead to expression of fusion genes (1). Following these developments, the classification of leukemia evolved from a morphology-based classification to the progressive, and still ongoing, inclusion of genetic-based criteria (2, 3). During the last decade, high-throughput sequencing technologies (often referred to as next-generation sequencing, NGS) have facilitated the establishment of almost complete maps of the genomic landscape of
leukemic cells in acute myeloid leukemia (AML) patients (4). In landmark studies by Timothy Ley and members of the Cancer Genome Atlas Research Network, the genome of a single AML patient was obtained in 2008. They later sequenced the whole genome of 24 selected AML cases but also the exomes of the progeny of hematopoietic stem and progenitor cells (HSPCs) taken from seven healthy individuals of different age (5, 6). Subsequently, they characterized the genomes of 200 clinically annotated adult cases of de novo AML either by whole-genome sequencing or exome sequencing along with RNA, miRNA sequencing, and DNA methylation analysis (7). Together with previous genetic and functional studies, several important observations can be highlighted. Firstly, the mutational rate of AML cells is lower than for most other cancers. Secondly, almost all samples had at least one mutation in genes of nine different categories [transcription factor fusions, nucleophosmin (NPM1), tumor suppressors, DNA-methylation-related genes, signaling mediators, chromatin modifiers, myeloid transcription factors, cohesin genes and spliceosome complex]. Thirdly, recurrent patterns of co-existence suggested functional cooperation as previously reported for transcription factor fusions/mutations [often referred to as “class II mutations”] and signaling mutations in tyrosine kinases or RAS-type GTPase (RAS) [often referred to as “class I mutations”] but also novel mutations targeting epigenetic regulators such as DNA methyltransferase 3a (DNMT3A) and isocitrate dehydrogenase (IDH)1/2 became apparent. Together with functional studies, these associations suggest that as little as two mutations in different categories might be sufficient to initiate leukemogenesis. Finally, the data obtained from healthy individuals suggested that the HSC compartment accumulates about 10–15 single-nucleotide variants every year. Over a decade later, the Children’s Oncology Group (COG)-National Cancer Institute (NCI) TARGET AML initiative was able to characterize the genomic landscape of almost 1,000 pediatric AML patients by whole genome sequencing of samples from 197 and targeted sequencing of tumor cells from 800 patients (8). This extensive effort revealed similarities but also important differences between adult and pediatric AML. First, the overall somatic mutation frequency in pediatric AML is lower than that in adult patients. Notably, the mutational burden increases with age, with fusions and focal copy number aberrations being more common in younger patients, whereas smaller sequence variants are more frequent in older individuals. Second, pediatric AML patients with fusions involving transcriptional regulators like lysine methyltransferase 2A (KMT2A), CBFA2/RUNX1 translocation partner 3 (CBFA2T3), or motor neuron and pancreas homeobox 1 (MNX1) tend to have few additional mutations and were associated with a particularly poor outcome. Third, distinct combinations of co-occurring alterations, such as the nucleoporin 98 (NUP98)–nuclear receptor binding SET domain protein 1 (NSD1) fusion and mutation of fms-related tyrosine kinase 3 (FLT3) or WT1 transcription factor (WT1), were observed, significantly affecting disease outcome. Fourth, alterations in signaling mediators such as N- or K-RAS and the receptor tyrosine kinases KIT and FLT3 appeared to be more prevalent than in adult patients. In contrast, mutations in DNMT3A, IDH1/2, NPM1, or tumor protein p53 (TP53) were less common in pediatric AML. Fourth, some “novel” pediatric-specific chromosomal copy number changes were found, including focal deletions in genes like muscleblind like splicing regulator 1 (MBNL1), zinc finger E-box binding homeobox 2 (ZEB2), E74-like ETS transcription factor 1 (ELF1), or interleukin 9 receptor (IL9R). Collectively, the TARGET AML initiative provided a comprehensive dataset of genetic alterations in pediatric AML that confirmed and extended previous observations indicating that similar to adult patients, pediatric AML is the product of a low number of cooperating mutations frequently involving transcriptional regulators affecting differentiation and self-renewal properties and mutations of signaling mediators (9) (Figure 1). Here, we focused on hallmarks of aggressive pediatric AML fusion oncogenes, including KMT2A, CBFA2T3, and NUP98 fusions.

Fusion Genes Associated With Aggressive Pediatric AML

The TARGET-AML study suggested that the association of pediatric AML with different fusion oncogenes strongly correlates with age of the patient (8) (Figure 1). Whereas, fusions involving KMT2A, CBFA2T3, or MNX1 are molecular hallmarks of AML affecting infants and early childhood (<3 years), those affecting the core binding factor (RUNX1 and CBFB) or the retinoid acid receptor (RARA) occur at any age but peak in children (3–14 years) or even in young adults (15–39 years). In addition, two particular NUP98 fusions, NUP98–lysine demethylation 5A (KDM5A, a.k.a. JARID1A, or RBP2) and NUP98–NSD1, are molecular hallmarks of cyogenetically silent infant or childhood AML, respectively.

The KMT2A (better known as mixed lineage leukemia, MLL) gene on the long arm of chromosome 11 (11q23) encodes a SET-domain histone methyltransferase that is important for the maintenance of the hematopoietic stem cells (10). KMT2A is the target of chromosomal translocations in adult and pediatric acute leukemia, mostly leading to fusions of the N-terminus of KMT2A with a large number of different partners, of which AF4/FMR2 family member 1 (AFF1, a.k.a. AF4), MLLT3 super elongation complex subunit (MLLT3, a.k.a. AF9), MLLT1 super elongation complex subunit (MLLT1, a.k.a. ENL), and MLLT10 histone lysine methyltransferase DOT1L cofactor (MLLT10, a.k.a. AF10) are the most prevalent (11). Although t(4;11)(q21;q23) leading to a KMT2A–AFF1 fusion is a molecular marker of infant acute lymphoblastic leukemia (ALL), it can occur at any age, and is rarely also found in AML. In contrast, t(9;11)(p22;q23) and ins(10;11)(p12;q23) leading to expression of KMT2A–MLLT3 and KMT2A–MLLT10 fusions appear more prevalent in pediatric than in adult AML. Interestingly, KMT2A–MLLT37 disease in infants presents more often as ALL than AML, whereas the phenotype changes into a typical myelo-monocytic AML M5 with increasing age of the patient. The difficulty to classify leukemia with KMT2A fusions, including lymphoid diseases, is also based on the fact that leukemic blasts retain a substantial amount of lineage...
infidelity and/or plasticity highlighted by frequent co-expression of myeloid markers and relapse of KMT2A+ B-ALL as AML (12). Functionally, it is currently thought that KMT2A fusions transform HSPCs by recruitment of a large super elongation protein complex (SEC) that activates transcription of target genes via directly influencing elongation by the RNA polymerase II (RNA-pol II). In addition, KMT2A fusion proteins also recruit the DOT1L histone 3 lysine 79 (H3K79me) methyltransferase that positively regulates expression of critical target genes (13) (Figure 2).

The importance of aberrant transcriptional control is furthermore highlighted by fusions between KMT2A and lysine acetyltransferase 6A (KAT6A a.k.a. Monocytic leukemia zinc finger protein, MOZ, or MYST3) or 6B [KAT6B a.k.a. Moz-related factor (MORF) or MYST4] to the histone acetyl transferases EP300 or CREBBP in some rare cases of pediatric myelodysplastic syndromes (MDS) and AML (14–16). In contrast to adult patients where MYST (MOZ/Ybf2/Sas2/Tip60) fusions are often associated with therapy-related AML, in pediatric patients, these fusions are found in congenital and perinatal leukemia. Interestingly, some infants with KAT2A-CREBBP+ AML were reported to go into spontaneous remission; however, the underlying biology remains poorly understood (17, 18).

The CBFA2T3 (a.k.a. ETO2 or MTG16) gene on the long arm of chromosome 16, encoding a transcriptional co-repressor, is targeted by two recurrent AML-associated chromosomal rearrangements, the t(16;21)(q24;q22) and the cytogenetically silent inv(16) (p13q24) leading to expression of RUNX1–CBFA2T3 and CBFA2T3–GLIS2 fusions, respectively. Whereas, the first is more prevalent in therapy-related adult AML and rarely found in pediatric patients, the second appears to be an exclusive pediatric lesion (19, 20). NGS strategies allowed the identification of the CBFA2T3–GLIS2 fusion from tumor cells of pediatric patients with de novo acute megakaryoblastic leukemia (non-DS AMKL) (21, 22). CBFA2T3–GLIS2 is the most prevalent chromosomal aberration of this disease entity followed by KMT2A, RBM15 (RNA-binding motif protein 15)-MRTFA (Myocardin related transcription factor A) (a.k.a. OTT-MAL), NUP98–KDM5A and other rare events (e.g., GATA2–HOXA9, MN1–FLI1, or NIPBL–HOXA9) (23). CBFA2T3–GLIS2 is not restricted to AMKL but can also be found in cytogenetically normal (CN) pediatric AML with different phenotypes (M0, M1, M2, M4, and M5, according to the FAB classification). Notably, AMKL patients are significantly younger than those with other AML phenotypes (24). Mechanistically, CBFA2T3–GLIS2 binds DNA, through CBFA2T3-associated transcription factors or directly through GLIS2 (GLIS family zinc finger 2) zinc-finger domains at enhancers and regulatory elements and leads to altered transcription and activity of key transcription factors like the upregulation of the ETS transcription factor ERG and a strong downregulation of GATA1 (25). Genetic
hijacking of ERG and GATA1 activities represents a common theme among pediatric AMKL as constitutive trisomy 21 (a.k.a. Down’s syndrome) AMKL disease progression is characterized by independent genetic alterations also impacting ERG (carried by chromosome 21) and GATA1 (Figure 3) (26, 27). Notably, additional mutations in cohesin components (~50% of patients), CTCF (~20% of patients), epigenetic regulators (~45% of patients), and signaling pathway intermediates (~45% of patients) may also re-enforce an ERG/GATA activity imbalance (28, 29). CBFA2T3–GLIS2 is also associated with aberrant expression of GLI-family target genes, including BMP factors, motivating evaluation of GLI inhibitors’ efficacy and specificity for this fusion (21, 22, 30).

The NUP98 gene on the short arm of chromosome 11 (11p15) encodes a structural component of the nuclear pore but the protein can also function as a transcriptional regulator (31). Similar to KMT2A, NUP98 is targeted by numerous chromosomal translocations or inversions in various but mostly myeloid hematological malignancies, leading to the expression of chimeric proteins containing the N-terminus of NUP98 fused to a large variety of different partners including several homeobox proteins (32). The best studied is t(7;11)(p15;p15), leading to a NUP98–HOXA9 fusion in MDS, chronic myeloid leukemia (CML) in blast crisis, and AML of any age. In contrast, the cytogenetically cryptic t(5;11)(q35;p15) and t(11;15)(p15;q35) translocations, leading to the expression of NUP98–NSD1 or NUP98–KDM5A fusions, respectively, are preferentially found in pediatric AML. NUP98–NSD1 contains the GLFG repeats of NUP98 fused to several PHD finger domains and the SET methyltransferase domain of NSD1 (33). NUP98–NSD1 is one of the most prevalent aberration in pediatric CN-AML, often presenting with a myelomonocytic phenotype (M4/M5; FAB) associated with poor outcome. Interestingly, in the majority of patients, tumor cells also harbor an internal tandem duplication in FLT3 (FLT3-ITD) and/or mutation in WT1 (34). NUP98–KDM5A was identified from a patient with megakaryoblastic leukemia and later shown to be present in about 10% of non-DS-AMKL (35, 36). NUP98–KDM5A contains the GLFG repeats of NUP98 fused to the C-terminal PHD finger domain of the KDM5A histone demethylase. Similar to KMT2A fusions or CBFA2T3–GLIS2, the presence of NUP98–KDM5A confers a poor clinical outcome (23). The mechanism of transformation by NUP98 fusions might involve the N-terminus containing GLFG repeats recruiting a large WDR82-SET1A/B-COMPASS (WSC) protein complex to promote trimethylation of lysine 4 of histone 3 (H3K4me)
focusing active transcription (37). On the other hand, the fusion partners appear also to contribute to alter target gene expression such as the HOX-A gene cluster by, e.g., H3K36 methylation (NUP98–NSD1) or by acting as a boundary factor that prevents spreading of repressive polycomb factors (NUP98–KDM5A) (38, 39) (Figure 4).

The MNX1 (a.k.a. HLXB9) gene on the long arm of chromosome 7 (7q36) encodes a homeobox transcription factor that is essential for pancreatic organogenesis, and motor-neuron differentiation, and is involved in a t(7;12)(q36;p13) translocation that is a hallmark of infant AML with poor outcome (8, 40). Although initial reports suggested that this translocation would lead to a chimeric fusion protein containing HLH and ETS domains of ETV6 joined to regulatory sequences and first exon of MNX1 lacking the homeodomain, it appeared that overexpression of MNX1 might be the primary consequence (41). The role of MNX1 in the hematopoietic system remains unclear. However, functional studies suggested that the protein might regulate cell–cell interaction and adhesion of leukemic cells and that aberrant expression of MNX1 leads to differentiation block in megakaryocyte-erythroid progenitor cells (42, 43).

**Signaling Mutations in Pediatric AML**

Mutations in signaling mediators such as receptor tyrosine kinases (e.g., FLT3 and KIT) and RAS-related molecules (e.g., N-RAS, K-RAS, PTPN11, or NF1) are found in adult and pediatric AML (8). These mutations generally lead to constitutive activation of interconnected signaling cascades that activate downstream effectors, such as signal transducers and activators of transcription (STAT), ELK, MYC, c-JUN, or NF-kB involved in transcriptional regulation of cell proliferation and survival.

The RAS proteins are a family of highly homologous low-molecular-weight proteins that bind GTP, located at the inner face of the plasma membrane. In the normal situation, the activity of RAS is controlled by hydrolysis of bound GTP by GTPase activating proteins (GAPs) and the replacement of bound GDP with fresh GTP, which is catalyzed by the family of guanine nucleotide exchange factors (GEFs) (44). About
20% of human cancers have activating point mutations of RAS most frequently affecting K-RAS, less N-RAS, and rarely H-RAS (45). The TARGET study reported N/K-RAS mutations in over 40% of investigated pediatric AML cases. Notably, the highest prevalence of RAS mutations was observed in infant patients that also harbored KMT2A fusions (8). Most cancer-associated RAS mutations affect codons 12, 13, and 61 and all compromise the GTPase activity of RAS, preventing GAPs from promoting hydrolysis of GTP on RAS and leading to the accumulation of RAS in the GTP-bound active form. G12D, G12V, G13D, and Q61H are the most prevalent RAS mutations in pediatric AML. Although the prognostic value of RAS mutations is an ongoing matter of debates, like other signaling mutations, they appear to affect the outcome by changing clonal expansion in AML (46).

The FLT3 protein is a class III receptor tyrosine kinase (RTK) family that contains an extra-cellular domain made up of five immunoglobulin-like regions, a single transmembrane region, an intracellular juxtamembrane domain (JMD), and two kinase domains at the carboxyl terminus. Inactivation studies in mice have shown that FLT3 signaling is central to the development of HSPC, B-cells, dendritic cell progenitors, and natural killer cells (47). Binding of FLT3-ligand (FL) leads to dimerization of FLT3 and autophosphorylation of tyrosine residues in the kinase domains, resulting in activation of multiple signaling cascades including RAS/RAF, PI3K/AKT, or STAT5, resulting in increased proliferation and survival. FLT3 is highly expressed in many hematological malignancies and often co-expressed with its ligand FL, suggesting autocrine signaling (48, 49). FLT3 is targeted by two categories of activating mutations, internal tandem duplication (ITD, variable in length) and tyrosine kinase domain (TKD) mutations. FLT3-ITD results in FL-independent dimerization, constitutive phosphorylation, and activation of downstream mediators. FLT3-ITD is found in about 10–20% of newly diagnosed pediatric AML patients and was reported to be an independent prognostic factor for poor outcome particularly for patients with high ITD allelic ratios and/or loss of the wild-type FLT3 allele leading to copy number-neutral ITD homozygosity (48). FLT3-TKD mutations mostly affecting aspartic acid D835 are less common (5–10%) than ITD and seem not to carry the same prognostic significance. Nevertheless, TKD mutation may also occur secondary at relapse of ITD+ patients that are treated with FLT3 inhibitors. Notably, FLT3-TKD mutations are particularly prevalent in pediatric leukemia patients with KMT2A fusions (50).
Mutations in Epigenetic Regulators

In contrast to adult AML, mutations in regulators of DNA methylation and histone modification including Ten-Eleven Translocation2 (TET2), IDH1 or IDH2, Enhancer of Zeste Homolog 2 (EZH2), DNMT3A, and Additional Sex Combs like-1 (ASXL1) are much less prevalent, affecting only about 1–2% of pediatric patients (51). Nevertheless, IDH1 or IDH2 mutations in codons 132 and 140, respectively, were found in over 10% of a cohort of CN pediatric AML mostly in combination with alterations of KMT2A, NUP98, and FLT3-ITD or RAS (52). DNMT methyltransferases (DNMT1, DNMT3A/B), the TET family of enzymes (TET1–3), and IDH1/2 are functionally interconnected (53). DNMTs methylate DNA cytosine residues that can be oxidized from 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) by TET enzymes in an iron- and α-ketoglutarate (α-KG)-dependent manner. The presence of an IDH1/2 mutation results in the production of 2-hydroxyglutarate (2-HG), which is structurally very similar to α-KG and competes with α-KG to inhibit α-KG-dependent enzymatic processes (53). Mouse models have shown that inactivation of TET2 and DNMT3A or targeted mutagenesis of IDH1/2 mostly induces preleukemic states and leads to AML development upon cooperation with additional mutations (54–56). Even though rare in pediatric patients, it is important to search for alterations of these factors, as novel approaches for therapeutic targeting (as outlined below) showed very promising results in adult AML.

MODELING GENETIC LESIONS IN PEDIATRIC AML

Development of recombinant DNA technologies allowed the cloning and characterization of a large number of genetic alterations identified in tumor cells from AML patients. To address their potential for induction and maintenance of a transformed phenotype, the cDNA of a gene of interest carrying a mutation or eventually an entire fusion gene is transferred into hematopoietic cells (cell lines or primary cells) mostly by recombinant retroviruses. Based on the limited access to primary material of a genetically rather heterogeneous disease as pediatric AML, the majority of functional studies are performed in animals, mostly mice. In vitro experiments measure the impact of an AML-associated mutation on proliferation and survival but also self-renewal and differentiation of bone marrow (BM)-derived HSPC. The latter two are often determined by measuring the serial replating capacity in growth factor-containing semisolid medium such as methylcellulose (MC). Expression of many KMT2A, NUP98, CBF, or RARA fusions support serial HSPC replating in MC associated with variable blockage of normal maturation. This assay also allows structure-function studies to dissect critical domains of a given gene product. To determine the transforming potential in vivo, researchers aim to express the respective cDNA/mini gene in HSPC of their animal model. In one widely used approach, mouse BM-derived cells are virally transduced to overexpress the respective genetic lesion and transplanted into irradiated syngenic recipients [often referred to as BM transplant (BMT) or reconstitution model] (57). Despite the drawbacks of often higher-than-physiological expression, viral integration, and transduction bias of multipotent progenitor cells, this assay allows relatively fast and easy-to-obtain insights into the leukemogenic potential of a given lesion. This strategy was used to show functional cooperation of transcription factor fusions (e.g., KMT2A–MLLT3, KMT2A–MLLT1, NUP98–HOXA9, RUNXI–RUNX1T1, PML–RARα, and others) with signaling mutations like FLT3-ITD, N-/K-RAS, or activating KIT mutations (58, 59). Nowadays, putative leukemogenic driver oncogenes can also be knocked into the mouse genome, resulting in expression regulated from its native promoter/enhancers. In addition, several chemically inducible transgenic mouse lines have been generated that identify the role of a mutation not only for induction but also for maintenance of a leukemic phenotype. Most likely, genome editing using Crispr/Cas9 will facilitate targeted recombination and eventually boost the development of novel AML animal models (60).

As the hematopoietic system of the mouse is not identical to the situation in humans, researchers developed transgenic mouse lines with a humanized hematopoiesis expressing several human hematopoietic regulatory genes in combination with defects of a normal immune response such as the MISTRG strain (61). These humanized mice not only allow to expand patient-derived AML cells but also to study the biology of the disease (62). Immunodeficient mice also allow to model the disease by transplanting human HSPCs engineered to virally overexpress a leukemia-associated fusion oncogene (63) or, more recently, obtained from the hematopoietic differentiation of induced pluripotent stem cells (iPSCs) derived from AML patient blasts (64, 65). Due to space constraints, we focus on some recent findings in mouse models related to those genetic lesions that are recurrently found in pediatric AML.

Modeling KMT2A Fusion-Driven Pediatric AML

KMT2A fusions, such as KMT2A–MLLT3, are among the best-studied AML-associated alterations. Transgenic knock-in as well as BMT models resulted in a myelo-monocytic AML that closely phenocopied the human disease (66). Strikingly, transduction of lineage-marker-depleted, Kit+ Sca1+ (LSK) cells, common myeloid progenitor (CMP), or granulocyte-macrophage progenitor (GMP) cells with viruses expressing KMT2A–MLLT3 or KMT2A–MLLT1 followed by transplantation resulted in a very similar disease (67). To dissect the activity of KMT2A–MLLT3 and KMT2A–MLLT1 in different cells of the hematopoietic hierarchy, we developed DOX-regulated transgenic mouse lines. As expected, we observed that KMT2A–MLLT3 is able to transform hematopoietic stem cells (HSC), but also more committed progenitor (CMP and GMP) cells. However, activation in long-term hematopoietic stem cells (LT-HSC) resulted in some animals in a particularly aggressive AML characterized by high expression levels of the transcription factors MECOM (MDS1 and EVI1 complex locus, a.k.a. EVI1) and ERG, which also characterize human AML with poor outcome (68). In contrast, using the same strategy, we found
that activation of KMT2A–MLLT1 preferentially transformed HSC, while CMP were transformed less efficiently and GMP were not transformed at all (69). This finding in transgenic mice might also reflect the situation in patients, as KMT2A–MLLT1 leukemic cells in patients often express lymphoid markers and are diagnosed as ALL or mixed lineage leukemia, whereas KMT2A–MLLT3 mostly present with AML-M5 (11). These observations in adult mice suggest that cells of the hematopoietic hierarchy have a differential sensitivity for a given leukemogenic fusion gene. In attempts to model pediatric KMT2A-rearranged AML, Chen et al. transplanted fetal liver-derived HSPC from a KMT2A–MLLT3 transgenic (knock-in) mice into wild-type mice and observed induction of a leukemic phenotype often expressing lymphoid surface markers after long latency. In contrast, transplantation of adult BM-derived cells led to the typical AML-M5 phenotype (70). Although differential grafting potential of highly cycling fetal liver-derived cells compared to adult BM cells might have influenced these experiments, pediatric but not adult KMT2A–MLLT3+ leukemia often express lymphoid markers, strongly suggesting that activation at a particular developmental stage significantly influences disease biology. However, so far, we are not aware of any animal model that appropriately phenocopies KMT2A fusion-driven pediatric AML.

**Modeling NUP98 Fusion-Driven Pediatric AML**

Multiple transgenic mouse models have shown that expression of several NUP98 fusions in the hematopoietic system results in various malignancies (32). Functional cooperation between NUP98–HOXA9 and BCR–ABL fusions became a widely used model to study CML in blast crisis (71, 72). Transgenic NUP98–HOXD13 mice, which develop myeloid dysplasia eventually progressing to AML, are often used to study molecular mechanisms of MDS (73). However, the transforming potential of the preferentially or exclusively pediatric NUP98 fusions (NUP98–KDM5A and NUP98–NSD1) is less clear. Transplantation of adult BM-derived HSPC retrovirally expressing the NUP98–KDM5A fusion resulted in a fully penetrant AML phenotype after 50–100 days, indicating a strong leukemogenic potential. Tumor cells expressed surface markers of early myeloid progenitor cells, but expression of megakaryoblastic markers observed in pediatric cases was not reported (40). Transplantation of adult BM-derived HSPC retrovirally expressing the NUP98–NSD1 fusion was reported to induce an AML phenotype in mice after a long latency with tumor cells expressing myeloid but also early stem cell-related (FLT3, CD34, and KIT) surface markers (38). However, using the same retroviral vector but a slightly different experimental strategy, we only observed development of AML upon cotransduction of NUP98–NSD1 together with FLT3-ITD, a mutation that is found in the majority of the patients (74). Even though these models indicate that NUP98–NSD1 has some transforming potential, alone it seems not sufficient to induce the disease. In addition, most of NUP98–NSD1+ AML occurring in children and younger adults present mostly with a myelomonocytic AML for which we currently do not have an appropriate model.

**Modeling Pediatric AMKL Fusion Oncogenes**

CBFA2T3–GLIS2, RBM15–MRTFA, NUP98–KDM5A, and KMT2A fusions are found in about 60–70% of non-DS-related pediatric AML. Additional rare fusions like GATA2–HOXA9, MN1–FLI1, NIPBL–HOXB9, or NUP98–BPTF were cloned from tumor cells from pediatric AMKL patients (75). Earlier work identified some JAK3 activating mutations in cell lines derived primarily from DS-AMKL, which induced a transient myeloproliferative disease with megakaryoblastic elements when retrovirally expressed in hematopoietic cells from Balb/c mice (76). Knock-in of the MRTFA cDNA at the endogenous Rbm15 locus led to bona fide Rbm15–MRTFA fusion expression in mice, altered clonogenic potential of fetal liver-derived hematopoietic cells, and AMKL with a low penetrance. Retroviral co-expression of the thrombopoietin receptor (MPL) carrying an activating mutation (W515L) induced leukemia with morphologic characteristics of AMKL; however, such a combination is rarely seen in patients (77). Using a similar approach to combine a transgenic model of Trisomy 21 (Ts1Rhr) with GATA1s and MPLW515L, Maligne et al. demonstrated that all three alterations were required to induce AMKL in mice (78, 79). Retroviral expression of CBFA2T3–GLIS2, GATA2–HOXA9, MN1–FLI1, and NIPBL–HOXB9 allowed serial replating of adult mouse BM-derived hematopoietic cells in MC associated with expression of megakaryocytic markers on some CBFA2T3–GLIS2- and MN1–FLI1-expressing cells. Consistently with the high homology between ERG and FLI1, transplantation of these MN1–FLI1-transduced cells was sufficient for the development of murine leukemia presenting clear features of AMKL (80, 81). However, GATA2–HOXA9- and NIPBL–HOXB9-transduced cells led to penetrant AML phenotypes but with limited megakaryocytic features, and CBFA2T3–GLIS2-transduced cells did not induce any disease (81). Of note, expression of RBM15–MRTFA was also not able to induce leukemia development using a retroviral transduction/BM transplant approach, suggesting that this approach is not suitable to model the leukemogenic activity of all fusion oncogenes (77). Very recent work suggested that transplantation of fetal liver hematopoietic cells retrovirally expressing the CBFA2T3–GLIS2 fusion in lethally irradiated recipients is able to induce an AMKL phenotype co-expressing the CD41 and CD61 megakaryocytic markers but with a limited penetrance (82). Together, these results indicate that better models are required to more faithfully recapitulate pediatric AMKL.

**Challenges to Accurately Model Pediatric Acute Leukemia in Mice**

The genetic heterogeneity, as well as the rareness of pediatric AML that limits access to primary cells, urges for the development of models that closely phenocopy the biology of the human disease. Establishment of appropriate models for pediatric leukemia is a challenging task illustrated by the efforts
to develop a mouse model for KMT2A–AFF1+ infant B cell ALL. The observation that KMT2A fusion+ infant leukemias have on average only about two non-silent mutations strongly suggests that the fusion might be sufficient for inducing the disease or that only very few cooperating hits are necessary (8, 83). Expression of a knocked-in KMT2A–AFF1 fusion ORF developed mostly B-cell lymphomas after a long latency in mice (84). An ALL phenotype developing after a relatively long latency was observed in mice carrying a conditional KMT2A–AFF1 allele, or by retroviral co-expression of KMT2A–AFF1 and the reciprocal AFF1–KMT2A fusion (85). More recently, Jim Mulloy et al. demonstrated that transplantation of human CD34+ HSPC retrovirally expressing a human–mouse chimeric KMT2A-Aff1 fusion developed pro-B-ALL after a latency of 100–250 days. In contrast, expression of this chimeric fusion in mouse HSPCs resulted in AML, whereas only low titers could be generated of viruses containing the fully human fusion ORF. Although this study was the first that indeed produced a KMT2A–AFF1-driven pro-B-ALL, the disease did not develop in “infant” or newborn mice (86). In another attempt to model KMT2A–AFF1 infant leukemia, Barrett et al. induced the fusion between developmental E12 and E14 to all definitive hematopoietic cells formed during embryonic development using a conditional invertor mouse strain controlled by the VE-Cadherin-cre recombinase. Expression of KMT2A–AFF1 at this early stage increased engraftment and self-renewal of fetal liver cells and provided the cells with a high clonogenic B-lymphoid potential; however, no early progression to B-ALL was observed (87). Interestingly, Menendez et al. earlier found the KMT2A–AFF1 fusion in BM mesenchymal stoma cells in affected patients, suggesting an early pre-hematopoietic precursor cell origin of the fusion (88). Of note, one cannot exclude that these observations are explained by species-related differences, inappropriate expression levels in cells at a particularly sensitive developmental stage, or the lack of a potential cooperative lesions.

Experiments based on transplantation of fetal liver- or BM-derived cells retrovirally expressing the NUP98–HOXA9 fusion into adult recipients revealed that the age of the cell of origin determines not only the latency period for disease development but also the lineage phenotype and changes of the BM niche (89). In the attempt to model Trisomy 21-associated AMKL, retroviral expression of ERG in murine adult BM leads to 100% of T-cell leukemia, while expression in E12.5 fetal liver cells generated erythro-megakaryocytic leukemia in 40–60% of recipient mice (90). Also, GATA1s and Trisomy 21 have been shown to induce stage-specific alterations of fetal hematopoiesis in both murine transgenic models and humans (91, 92). Proof of concept that neonatal hematological malignancies can also be induced in mice was provided by experiments that modeled juvenile myelomonocytic leukemia (JMML). Hereby, either fetal expression of KrasG12D controlled by Flt3-cre recombinase or constitutive co-deletion of Cbl/Cbl-b resulted in aggressive neonatal myeloproliferative disorders that were lethal within 2–3 weeks after birth (93, 94).

It is very likely that the type of hematopoietic stem or progenitor in which the mutation/fusion first appears is of importance for both development and phenotype of pediatric AML. Although under considerable debates, the normal hematopoietic hierarchy is constituted of a continuum of progenitors presenting different self-renewal and differentiation potential (95, 96). Notably, there is increasing evidence that the fetal and adult hematopoietic hierarchies significantly differ in structure and composition (97). Although not yet demonstrated in murine models of pediatric AML, several AML oncogenes (including KMT2A–MLLT3) studied in an adult context are able to transform both HSC and more committed progenitors (e.g., GMP) while others are not able to do so (67, 98–101). Also, as indicated above, the phenotype of KMT2A–MLLT3+ and KMT2A–MLLT1+ leukemia was dependent on the stage of the hematopoietic hierarchy in which the driver mutation was expressed (68, 69). Recently, some studies have reported the successful derivation of iPSCs from human AML cells, including from blasts presenting MLL fusions, suggesting that this approach can generate human-based preclinical models (64, 65, 102, 103). Although the frequency of successful iPSC reprogramming from AML blasts is likely low, iPSC-derived hematopoiesis followed by transplantation into immunodeficient models may represent a future opportunity to investigate specific stages of the human fetal hematopoietic development that are difficult to access using primary human samples (104).

Collectively, these studies indicated several factors to be taken into account for appropriately modeling pediatric AML in mice: (1) driver (and eventually also cooperating) mutations most likely need to be active in utero; (2) a driver and cooperating lesion might not occur and/or be active at the same developmental stage; (3) a given genetic lesion (e.g., fusion gene) has its optimal expression level; and (4) particular developmental cell stages or identity are likely more permissive to transformation than others (Figure 5).

MOLECULAR TARGETING OF PEDIATRIC AML

Functional cooperation studies in cellular and animal models suggest that we can group AML-associated mutations into drivers that are essential for induction and maintenance of the disease, and cooperating mutations that support expansion of the malignant clone or may facilitate transformation by mostly metabolic modifications (101). As a consequence, inactivation or degradation of the driver might represent the most promising approach for long-term cure of the disease. However, in cases without a clearly defined driver, inhibition of other cooperating lesions (such as constitutive active protein kinases) or interfering with more general dependencies of transformed hematopoietic cells might provide an alternative strategy (Figure 6). Here, we discuss selected targeting strategies for pediatric AML that are either effective in the clinic, being explored in ongoing trials or just demonstrated as proof of concept in preclinical models.

Targeting the Driver Mutation (e.g., Fusion Oncogene)

Positive proof of concept that long-term cure can be achieved in AML patients through inactivation of the driver mutation comes from acute promyelocytic leukemia (APL) that is, in the vast majority of the cases, driven by the PML–RARα fusion resulting from t(15;17)(q22;q11). Although, the TARGET
Increasing evidence suggests that pediatric AML-associated oncogenes have a particular window of opportunity during development to transform hematopoietic cells. GATA1s and Trisomy 21 have been shown to induce stage-specific alteration of fetal hematopoiesis (86). For KMT2A–AFF1+ leukemia, the fusion was found not only in hematopoietic precursors but also in BM stroma cells (83), suggesting that the fusion might target a very early precursor cell that maintain some mesenchymal properties. Together, these observations suggest that both the developmental stage and the type of cell in the hematopoietic hierarchy in which a genetic alteration occurs determine whether leukemia will develop and the associated disease phenotype and aggressiveness.

pediatric AML study did not report PML–RARA+ APL patients, who are often considered separately for therapeutic reasons, they make up to of 5–10% of pediatric AML patients in the United States (105). Notably, about 10% of the pediatric cases clinically presenting as APL seem not to carry any RARA fusion (106). Several transgenic mouse models have shown that the PML–RARA fusion is essential but most likely not sufficient to induce the disease as it cooperated with other mutations such as FLT3-ITD (107). Pioneer work by Hughes de Thé and Zhu Chen demonstrated that pharmacological doses of all trans retinoic acid (ATRA) or arsenic trioxide (As2O3) induce different molecular mechanisms that ultimately lead to proteasome-dependent degradation of the PML–RARA fusion protein (108). A phase III randomized multicenter trial demonstrated clinical efficacy and superiority of the combination of ATRA with As2O3 over ATRA and chemotherapy in adult patients (109). Pediatric APL patients treated with ATRA and anthracyclines or As2O3 reached an estimated overall 5- and 8-year survival of >95% (106). Collectively, these observations strongly suggest that targeted degradation of a driver fusion oncogene is the strategy of choice for long-term cure of a significant fraction of AML patients.

Multiple mouse models demonstrated that several KMT2A fusions are strong leukemogenic oncogenes that drive the disease in the presence of few, if any, cooperating mutations (66, 110). We were able to show that induction and maintenance of a transformed state of murine hematopoietic cells by the KMT2A–MLLT3 or KMT2A–MLLT1 is dependent on the fusion dose and is fully reversible (68, 69), indicating that targeted reduction of the fusion protein might be sufficient to induce differentiation and dissolve the leukemic phenotype. Biochemical studies suggested that leukemogenic KMT2A fusions form large protein complexes that bind to and activate KMT2A targets in an uncontrolled manner (111). Recent experimental work suggests that KMT2A fusion-mediated transformation could be impaired by stabilization of the non-rearranged protein, which naturally
FIGURE 6 | Potential therapeutic targeting of functionally cooperating molecular mechanisms. Personalized efficient AML therapies will most likely be based on a combination of strategies that target the driver mutation (A), cooperating processes (B), and general characteristics of the transformed state (C). Targeting the driver can be achieved by degradation of the fusion oncogene (e.g., as shown for PML–RARA by ATRA and arsenic) and blocking critical protein–protein interactions (e.g., MENIN–KMT2A interaction for chromosome binding of KMT2A fusions), related enzymatic activities, or essential downstream targets. Cooperating mutations, including constitutive active protein tyrosine kinases or RAS proteins, can be targeted with highly selective and potent small-molecule inhibitors (e.g., FLT3 inhibitors). The transformed state can be impaired by blocking survival by primed BH3-apoptosis regulators (e.g., BCL2, MCL1) or by targeting altered metabolism-related regulators (e.g., mutated IDH1/2).

undergoes proteasomal degradation regulated by casein-kinase II and IRAK4-dependent phosphorylation events (112, 113). The transforming potential of KMT2A fusions depends on several protein–protein interactions as well as enzymatic activities that have the potential for therapeutic interference. Interaction of the N-terminus of KMT2A with MENIN and the adapter protein LEDGF is essential to bind to critical targets and productive transformation by KMT2A fusion genes (114). Structure-function studies identified critical interphases, and small molecules were developed that disrupted binding of MENIN to KMT2A and impaired KMT2A fusion transformation (115–117). Constant optimization allowed the generation of MENIN protein–protein interaction (PPI) inhibitors that impair the viability of KMT2A fusion-driven cells at a nanomolar concentration (118). Notably, MENIN PPI inhibitors were shown to have potent anti-cancer activity not only in KMT2A fusion-driven leukemia but also in prostate tumors (119, 120). Novel, more potent and stable MENIN PPIs with increased selectivity for KMT2A fusions have been presented at ASH 2018 with potent anti-leukemic activity in patient-derived xenotransplant (PDX) models of AML (121).

KMT2A fusion complexes recruit the DOT1L histone H3 lysine 79 (H3K79) methyltransferase that positively regulates expression of the target genes most likely by preventing association of the sirtuin-1 (SIRT1) deacetylase complex resulting in loss of H3K9 and H4K16 acetylation, and reduced SUV39-mediated methylation on H3K9m3 (122). The maintenance of a KMT2A fusion-induced transformed state showed high dependence of DOT1L-mediated H3K79 methylation and small-molecule DOT1L inhibitors showed promising anti-tumor activity in vitro and in vivo in preclinical models (123). However, although application of a DOT1L inhibitor (Pinometostat, a.k.a. EPZ-5676) reduced H3K79 methylation, only modest clinical activity was observed in adult patients with KMT2A rearranged leukemia (124).

In addition to MENIN/LEDGF or DOT1L, targeted interference with other components of the KMT2A fusion complexes (e.g., WDR5, BRD4, CDK9) have been explored in various preclinical models (125). Interestingly, AML cells carrying CEBPA mutations leading to expression of the short oncogenic CEBPα p30 isoform appear sensitive to pharmacological targeting of the KMT2A complex (126). However, so far, no strategy has been reported that allows selective degradation of KMT2A fusion proteins to replicate the success in APL.

Studies with Drosophila cells showed that NUP98 acts as a transcriptional activator physically interacting with non-specific lethal (NSL) and Trithorax (KMT2A) protein complexes (127).
More recent work suggested that NUP98 and some NUP98 fusion proteins (NUP98–HOXA9, NUP98–NSD1, and NUP98–HOXD13) physically interact with proteins of the human NSL and KMT2A complexes such as WDR5 or MOF most likely through the GLFG repeats (37, 128). Notably, conditional genetic ablation of KMT2A significantly reduced the leukemogenic activity of the NUP98–HOXA9 fusion in vivo. In addition, KMT2A-dependent gene expression signatures from murine NUP98–HOXA9 transformed cells resembled human NUP98–NSD1-derived profiles, suggesting at least overlapping pathways. These observations suggest that therapeutic targeting of KMT2A would also be effective against NUP98 fusion-driven AML. However, more translational studies found significant differences in gene expression signatures of pediatric AML cases harboring either KMT2A fusions or NUP98–NSD1. Indeed, whereas the first group is often characterized by increased expression of ETV1, the latter is associated with increased expression of another PRDM family member PRDM16 (a.k.a. MELI) (32, 129, 130). Nevertheless, the activity of leukemogenic NUP98 fusions might be impaired by blocking the activities of distinct partner genes. Leukemic blasts immortalized by retroviral expression of the NUP98–NSD1 fusion showed elevated levels of H3K36me marks on productive target genes including the Hox-A gene clusters leading to the idea that small molecules blocking the NSD1 SET methyltransferase domain might have anti-leukemic activity (38, 131). Interestingly, disulfiram (DSF), known for its aldehyde dehydrogenase blocking activity, was found to induce apoptosis of murine myeloblasts transformed by PHD-containing NUP98–KDM5A and NUP98–PHF23 fusions. Although the detailed molecular mechanism remains unclear, it appeared that DSF blocked the interaction of the fusion proteins with the promoters of critical downstream targets like Hoxa7-10, Meis1, and Hoxb5 (132).

Although the use of high-dose cytarabine has improved the outcome of core binding factor (CBF) AML, we still lack efficient strategies to selectively inactivate the RUNX1–RUNX1 partner transcriptional co-repressor 1 (RUNX1T1, a.k.a. CBFA2T1 or ETO) or CBFB–MYH11 driver fusions. Earlier work found that oligomerization of RUNX1–RUNX1T1 through the nervous homology 2 (NHR2) domain of RUNX1T1 was essential for its activity as a transcriptional corepressor and mediator of self-renewal to BM cells (133). Interfering with tetramerization by peptides and by small molecules reduced the oncogenic activity of the RUNX1–RUNX1T1 fusion in preclinical models (134, 135). RUNX1–RUNX1T1 seems to form stable complexes containing hematopoietic co-factors including E-proteins, of which the interaction, e.g., between the NHR2 domain of RUNX1T1, with a novel binding motif in E proteins seems critical (136). The oncogenic potential of the RUNX1–RUNX1T1 fusion was also shown to depend on EP300-mediated acetylation of distinct lysine (K24, K43) lysine residues; hence, blocking EP300 activity impaired leukemic transformation (137). Pioneer work by Illendula et al. provided a novel concept to molecularly target CBFB–MYH11+ AML. They developed a small molecule (AI-10–49) that selectively binds the CBFB–MYH11 fusion protein, resulting in RUNX1-mediated repression of the potent oncogenic driver MYC (138, 139). CBFA2T3 is highly homologous to RUNX1T1 containing nervous homology domains (NHR1–3) that mediate oligomerization of the AMKL-associated CBFA2T3–GLIS2 fusion. Notably, overexpression of a small NHR2 peptide (NC128) was able to significantly reduce the leukemia development of a CBFA2T3–GLIS2+ human AML cell line in immunodeficient mice (25). Collectively, the oncogenic activity of CBF-related fusions can be impaired by interfering with oligomerization (RUNX1–RUNX1T1 and CBFA2T3–GLIS2) and post-translational modification (RUNX1–RUNX1T1) or by impairing binding to RUNX1 (CBFB–MYH11); however, no such strategies were so far successfully translated into the clinic.

**Targeting Cooperating Mutations (e.g., Tyrosine Kinase Mutation)**

Several small molecules have been established that block the uncontrolled activity of FLT3-ITD, ranging from pan-kinase inhibitors like Sunitinib, to promiscuous inhibitors of multiple tyrosine kinases including Sorafenib, Midostaurin (a.k.a. PKC412), or Lesartuminib (a.k.a. CEP-701), to very selective compounds such as Quizartinib (a.k.a. AC220), Tandutinib (a.k.a. MLN518), Crenolanib, or Gilteritinib (a.k.a. ASP2215) (140). Based on an international randomized controlled study showing that the combination of Midostaurin and chemotherapy improved the outcome of adult AML patients, the drug recently became FDA-approved for therapy of de novo FLT3-mutated AML (141). Very recently, Gilteritinib was also FDA-approved for relapsed/refractory AML with FLT3 mutations based on results from the ADMIRAL trial (142). Several FLT3 inhibitors have been explored in small clinical trials in pediatric AML patients, and partial or complete responses were reported not only in KMT2A-rearranged ALL (Midostaurin, Lestaurtinib), but also in refractory/relapse AML (Sorafenib) (143). Promising results have been reported with the combination of the selective FLT3 inhibitor Quizartinib with chemotherapy in children with relapse or refractory AML or KMT2A-rearranged ALL (144). However, more selective FLT3 inhibition has been linked to resistance mutations in FLT3-ITD+ AML, particularly affecting the gatekeeper (F69L) or activation loop (D835/I836) residues (145). Future prospective controlled clinical studies will be necessary to show the profit and risks of selective FLT3 inhibition in pediatric AML.

Based on in vitro and in vivo cooperation in AML, targeted inhibition of constitutive active mutant RAS should be of therapeutic benefit. Although long viewed to be undruggable, recent observations suggest that pharmacological inhibition of RAS could be achieved (146, 147). Earlier targeting attempts focused on interfering with RAS posttranslational modification and farnesyltransferase inhibitors like Sorafenib, Midostaurin (a.k.a. PKC412), or Lestaurtinib (a.k.a. MLN518), Crenolanib, or Gilteritinib (a.k.a. ASP2215) (140). Based on an international randomized controlled study showing that the combination of Midostaurin and chemotherapy improved the outcome of adult AML patients, the drug recently became FDA-approved for therapy of de novo FLT3-mutated AML (141). Very recently, Gilteritinib was also FDA-approved for relapsed/refractory AML with FLT3 mutations based on results from the ADMIRAL trial (142). Several FLT3 inhibitors have been explored in small clinical trials in pediatric AML patients, and partial or complete responses were reported not only in KMT2A-rearranged ALL (Midostaurin, Lestaurtinib), but also in refractory/relapse AML (Sorafenib) (143). Promising results have been reported with the combination of the selective FLT3 inhibitor Quizartinib with chemotherapy in children with relapse or refractory AML or KMT2A-rearranged ALL (144). However, more selective FLT3 inhibition has been linked to resistance mutations in FLT3-ITD+ AML, particularly affecting the gatekeeper (F69L) or activation loop (D835/I836) residues (145). Future prospective controlled clinical studies will be necessary to show the profit and risks of selective FLT3 inhibition in pediatric AML.

Based on in vitro and in vivo cooperation in AML, targeted inhibition of constitutive active mutant RAS should be of therapeutic benefit. Although long viewed to be undruggable, recent observations suggest that pharmacological inhibition of RAS could be achieved (146, 147). Earlier targeting attempts focused on interfering with RAS posttranslational modification and farnesyltransferase inhibitors like Sorafenib, Midostaurin (a.k.a. PKC412), or Lestaurtinib (a.k.a. MLN518), Crenolanib, or Gilteritinib (a.k.a. ASP2215) (140). Based on an international randomized controlled study showing that the combination of Midostaurin and chemotherapy improved the outcome of adult AML patients, the drug recently became FDA-approved for therapy of de novo FLT3-mutated AML (141). Very recently, Gilteritinib was also FDA-approved for relapsed/refractory AML with FLT3 mutations based on results from the ADMIRAL trial (142). Several FLT3 inhibitors have been explored in small clinical trials in pediatric AML patients, and partial or complete responses were reported not only in KMT2A-rearranged ALL (Midostaurin, Lestaurtinib), but also in refractory/relapse AML (Sorafenib) (143). Promising results have been reported with the combination of the selective FLT3 inhibitor Quizartinib with chemotherapy in children with relapse or refractory AML or KMT2A-rearranged ALL (144). However, more selective FLT3 inhibition has been linked to resistance mutations in FLT3-ITD+ AML, particularly affecting the gatekeeper (F69L) or activation loop (D835/I836) residues (145). Future prospective controlled clinical studies will be necessary to show the profit and risks of selective FLT3 inhibition in pediatric AML.
with distinct RAS mutations: compounds were identified that block K-RAS\textsuperscript{G12C} by forming covalent disulfide bridges with the cysteine. Other compounds were found to block GDP-bound K-RAS\textsuperscript{G12C} and selectively impair cancer growth. Impairing RAS activity by blocking the interaction with downstream mediators, genetic depletion by anti-sense oligos, or interfering with RAS dimerization also suggested that pharmacological targeting could be achieved. However, clinical translation of targeting mutated RAS in cancer has not yet been achieved.

In contrast to adult AML, mutations in the genes encoding for IDH1 and IDH2 are rare in pediatric AML (51, 52). However, small molecules were generated that potently and selectively inhibit mutant IDH1 or IDH2 through binding in an allosteric manner at the interface of the dimerized enzymes (149, 150). IDH1\textsuperscript{R132H/C} - or IDH2\textsuperscript{R140Q}-selective inhibitors were shown to induce differentiation of primary AML cells in vitro and in PDX models, leading to a statistically significant survival benefit (151). Phase I/II clinical trials with Ivosidenib (targeting IDH1-R132) and Edasidenib (targeting IDH2\textsuperscript{R140Q}) in refractory or relapsed adult AML patients show overall response rates >40% with about 20% complete remission over several months underlining the potential for these compounds for personalized therapeutic strategies (152, 153). However, some patients developed clinical resistance to Edasidenib by secondary mutations in trans, in the IDH2 allele without the neomorphic R140Q mutation (154). Despite these limitations, the fact that IDH1/2 mutations can be selectively blocked by clinically effective small-molecule inhibitors urges for clinical trials in pediatric AML patients.

Targeting Hallmarks of Transformed Cells and the Immune System

It is well-known that malignant transformation leads to various cellular dependencies that may offer targets for therapeutic intervention (155). A very promising emerging strategy is to interfere with the cells’ capability to evade programmed cell death known as apoptosis. In a simplified view of this complex regulatory pathway, apoptotic cell death is prevented by pro-survival BCL2-like proteins (e.g., BCL2, BCL2L1: a.k.a. BCL-XL, MCL1) by keeping in check the cell death effector proteins BAX and BAK that are activated by BH3-only proteins (e.g., BCL2L1: a.k.a. BIM; BBC3: a.k.a. PUMA, BAD, BID; PMAIP1: a.k.a. NOXA) (156). Small molecules (e.g., Venetoclax, a.k.a. ABT-199) that mimic the function of BH3-only proteins (“BH3-mimetics”) have been developed that are inducing apoptosis not only in lymphoid neoplasms like CLL or B-cell non-Hodgkin’s lymphoma but also in myeloid neoplasms including AML (157, 158). Selective BCL2 inhibition by Venetoclax induces rapid cell death in AML cells with an IC\textsubscript{50} as low as 10 nmol/L (159). A phase II study revealed that Venetoclax monotherapy has potent anti-leukemic activity in high-risk relapsed/refractory adult AML patients (160). Small-molecule MCL1 inhibitors (e.g., VU661013, AMG176) were shown to be synergistic and rescued Venetoclax resistance of AML cells (161, 162). In addition, Venetoclax showed synergistic therapeutic activity in combination with other drugs including low-dose cytarabine, JAK1/2 inhibitors, or DNMT1 inhibitors (decitabine, azacytidine) (163–165). Moreover, inhibition of BCL2 was found to enhance the anti-leukemic activity of FLT3 inhibitors (Midostaurin, Gilteritinib) in preclinical AML models (166). Very recent work suggested that TP53, the apoptotic signaling network, and the mitochondrial functionality are the drivers of Venetoclax sensitivity in AML cells (167). These observations in adult AML patients initiated some studies to explore Venetoclax in pediatric patients with relapse/refractory malignancies including acute leukemia (NCT03236857) (168).

Intensive research is currently ongoing that aims to therapeutically target the capacity of pediatric leukemia cells to escape destruction by the immune system (169). Some studies reported some significant therapeutic responses in AML treated with antibody-drug conjugates (ADCs) targeting surface molecules like Gemtuzumab, a calicheamicin-conjugated antibody against CD33 and the response seems to correlate with a splicing polymorphism affecting the antibodies’ binding site (170). Potent anti-leukemic activity has been reported for bispecific T-cell engaging antibodies (BiTEs) targeting T-cell CD3 and CD19 (Blinatumomab) on B-cell ALL cells leading to FDA approval to treat pediatric B-ALL (171). Several BiTEs targeting some AML-associated surface proteins (CD33, CD123, and CD37) that have shown potent experimental activities are currently undergoing clinical trials (172). The immunotherapy revolution in pediatric hematologic cancers is mostly marked by the development of chimeric antigen receptor T-cells (CAR-T). Remarkable success was reported by targeting CD19 on relapsed/refractory B-ALL patients (173). CAR-T approaches to target AML-associated antigens (CD33 and CD123) have been explored in preclinical models, but it appeared that yet to be defined more tumor cell-selective epitopes might be necessary to reach the efficacy observed in B-ALL (174). Very recent experimental studies suggested improved anti CD33 CAR-T therapy for AML by genome editing-mediated ablation of CD33 in HSC (175, 176). Finally, the success of checkpoint inhibitors mostly antibodies targeting immune suppressive antigens such as PD-1, PD-L1, or CTLA-4 in some solid tumors associated with a high mutational burden such as malignant melanoma initiated intensive study for their potential in hematological malignancies including AML (177). PD-1 and/or PD-L1 are expressed in AML cells, and their blockade coupled with depletion of regulatory T-cells showed potent anti-leukemic activity in preclinical models (178). Several monoclonal antibodies (e.g., Nivolumab, Pembrolizumab, Durvalumab, and Ipilimumab) are currently studied for their anti-leukemic potential in refractor/refractory AML patients; however, checkpoint inhibitors alone seem to be much less effective in AML than in solid cancers (179).

AUTHOR CONTRIBUTIONS

Both authors have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
FUNDING

JS was supported by the Swiss National Science Foundation (SNF 31003A_173224/1), the Swiss Cancer League (KFS-3487-08-2014), Cancer League beider Basel, the San Salvatore Foundation (Lugano Switzerland), the Wilhelm Sander Foundation (Munich), and the Novartis Foundation for Biomedical Research. TM was supported by Institut National du Cancer (INCA: PLBIO-2014-176 and PLBIO-2018-169), Ligue contre le cancer: équipe labellisée, PAIR-Pédiatrie/CONECT-AML (Collaborative Network for Children and Teenagers with Acute Myeloblastic Leukemia: INCA-ARC-LIGUE_11905 and Association Laurette Fugain), and Société Française des cancers de l’Enfant.

ACKNOWLEDGMENTS

The authors thank present and past members of their laboratories for the fruitful contributions and vivid science. In particular, we thank Neil Fisher for critically reading the manuscript.

REFERENCES

1. Rowley JD. Chromosomal translocations: revisited yet again. Blood. (2008) 112:2183–9. doi: 10.1182/blood-2008-04-097931
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemias. French–American–British (FAB) co-operative group. Br J Haematol. (1976) 33:451–8. doi: 10.1111/j.1365-2141.1976.tb03563.x
3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. (2016) 127:2391–405. doi: 10.1182/blood-2016-03-643544
4. Braggio E, Esan J, Fonseca R, Stewart AK. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J. (2013) 3:e127. doi: 10.1038/bjc.2013.26
5. Ley TJ, Mardis ER, Miller CA, Larson DE, Koboldt DC, et al. The Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. (2013) 368:2059–74. doi: 10.1056/NEJMoa1301689
6. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koholidt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. (2012) 150:264–78. doi: 10.1016/j.cell.2012.06.023
7. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. Nature. (2008) 456:66–72. doi: 10.1038/nature07485
8. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koholidt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. (2012) 150:264–78. doi: 10.1016/j.cell.2012.06.023
9. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. (2013) 368:2059–74. doi: 10.1056/NEJMoa1301689
10. Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonso TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. (2018) 24:103–12. doi: 10.1038/s41591-017-0044-x
11. de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. (2018) 24:103–12. doi: 10.1038/s41591-017-0044-x
12. de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. (2018) 24:103–12. doi: 10.1038/s41591-017-0044-x
13. de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. (2018) 24:103–12. doi: 10.1038/s41591-017-0044-x
32. Gough SM, Slape CJ, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. *Blood*. (2011) 118:2647–57. doi: 10.1182/blood-2011-07-328880
33. Iaju RJ, Fidler A, Haas OA, Strickson AJ, Watkins F, Clark K, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;pl5.5) in de novo childhood acute myeloid leukemia. *Blood*. (2001) 98:1264–7. doi: 10.1182/blood.V98.4.1264
34. Holllink IH, van den Heuel-Eibrink MM, Arentsen-Peters ST, Praetcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. *Blood*. (2011) 118:3645–56. doi: 10.1182/blood-2011-04-346643
35. van Zutven LJ, Oren E, Velthuizen SC, van Drunen E, van Bergh AR, van den Heuel-Eibrink MM, et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. *Genes Chromosomes Cancer*. (2006) 45:437–46. doi: 10.1002/gcc.20308
36. de Rooij JD, Holllink IH, Arentsen-Peters ST, van Galen JE, Berra-Vellooro H, Baruchel A, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. *Leukemia*. (2013) 27:2280–8. doi: 10.1038/leu.2013.97
37. Franks TM, McCloskey A, Shokirev MN, Benner C, Rathore A, Hetzer MW. Nup98 recruits the Wdr82-Set1A/COMPASS complex to promoters to regulate H3K4 trimethylation in hematopoietic progenitor cells. *Genes Dev*. (2017) 31:2222–34. doi: 10.1101/hdev.306753.117
38. Wang GG, Pasillas MP, Kamps MP. NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. *Nat Cell Biol*. (2017) 19:847–51. doi: 10.1038/ncb3608
39. Wang GG, Song J, Wang Z, Dorrman HL, Casadio F, Li H, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. *Nature*. (2009) 459:847–51. doi: 10.1038/nature08036
40. Berra-Vellooro HB, Panagopulos I, Isaksun M, van Wering E, van Drunen E, de Klein A, et al. Fusion of the homeobox gene Hlx89 and the ETv6 gene in infant acute myeloid leukemias with the (7;12)(q36;p13). *Cancer Res*. (2001) 61:5374–7.
41. Tou S, Mostafa Kamel Y, Owoka T, Federico C, Truong TH, Saccone S. Paediatric acute myeloid leukemia with the (7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspects. *Biomark Res*. (2015) 3:21. doi: 10.1186/s40364-015-0041-4
42. Wildenhain S, Ingenhaged D, Ruckert C, Degistirici O, Dugas M, Meisel R, et al. Humanized murine models of acute myeloid leukemia that originating in postnatal marrow. *Hemasphere*. (2014) 4:263. doi: 10.3389/fonc.2014.00263
43. Ljung DC, Liu HC, Yang CP, Jiang TH, Hung JJ, Yeh TC, et al. Cooperation of mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDHI, IDH2, and DNMT3A. *Blood*. (2013) 121:2988–95. doi: 10.1182/blood-2012-06-436782
44. Berra-Vellooro H, Baruchel A, et al. Modeling epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia. *Haematologica*. (2014) 99:e130–2. doi: 10.3324/haematol.2014.108235
45. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. *Blood*. (2013) 121:3563–72. doi: 10.1182/blood-2013-01-451781
46. Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barrelyo R, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. *Cancer Cell*. (2015) 27:502–15. doi: 10.1016/j.ccell.2015.03.009
47. Almosailleakh M, Schwaller J. Murine models of acute myeloid leukemia. *Int J Mol Sci*. (2019) 20:4E53. doi: 10.3390/ijms20020453
48. Chan IT, Kato K, Williams IR, Cohen S, Moore S, Shigematsu H, et al. Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. *Blood*. (2006) 108:1708–15. doi: 10.1182/blood-2006-04-015040
49. Zhao L, Melenhorst JJ, Alemu L, Kirby M, Anderson S, Kench M, et al. Kit with D816 mutations cooperates with Ckbf--MYH11 for leukaemogenesis in mice. *Blood*. (2012) 119:1511–21. doi: 10.1182/blood-2011-03-332810
50. Shi X, Kitano A, Jiang Y, Luiu V, Hoegenaer KA, Nakada D. Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells. *Exp Hematol*. (2018) 64:33–44.e35. doi: 10.1016/j.exphem.2018.04.009
51. De La Rochere P, Guilla L, Deacaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. *Trends Immunol*. (2018) 39:748–63. doi: 10.1016/j.it.2018.07.001
52. Gopalakrishnapillai A, Kolb EA, Dhanan P, Bojja AS, Mason RW, Cora D, et al. Generation of pediatric leukemia xenograft models in Nsg-B2m Mice: comparison with NOD/SCID Mice. *Front Oncol*. (2016) 6:162. doi: 10.3389/fonc.2016.00162
53. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. *Science*. (2007) 316:600–4. doi: 10.1126/science.1139851
54. Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinsch A, Corces MR, et al. Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease. *Cell Stem Cell*. (2017) 20:329–44.e327. doi: 10.1016/j.cccel.2016.11.018
55. Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. *Cell Stem Cell*. (2017) 20:315–28.e317. doi: 10.1016/j.ccell.2017.01.009
56. Milne TA. Mouse models of MLL leukemia: recapitulating the human disease. *Blood*. (2017) 129:2217–23. doi: 10.1182/blood-2016-10-691428
57. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. *Genes Dev*. (2013) 27:3029–35. doi: 10.1101/gad.1143403
58. Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. *Cancer Cell*. (2016) 30:43–58. doi: 10.1016/j.ccell.2016.05.011
59. Stavropoulou V, Almosailleakh M, Royo H, Spetz JF, Juge S, Brault L, et al. A novel inducible mouse model of MLL-ENL-driven mixed lineage leukemia. *Hematosphere*. (2018) 2:e251. doi: 10.1007/s8599900000000051
60. Chen W, O'Sullivan MG, Hudson W, Kersey J. Modeling human infant MLL leukemia in mice: leukemia from fetal liver differs from that originating in postnatal marrow. *Blood*. (2011) 117:3474–5. doi: 10.1182/blood-2010-11-317529
71. Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. *Proc Natl Acad Sci USA.* (2002) 99:7622–7. doi: 10.1073/pnas.102583199.

72. Mayotte N, Roy DC, Yao J, Koon E, Sauvageau G. Oncogenic interaction between BCR/ABL and NUP98–HOXA9 demonstrated by the use of an *in vitro* purging culture system. *Blood.* (2002) 100:4177–84. doi: 10.1182/blood-2002-04-1244.

73. Lin YW, Scape C, Zhang Z, Aplan PD. NUP98–HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. *Blood.* (2005) 106:287–95. doi: 10.1182/blood-2004-12-4794.

74. Thanasopoulou A, Tzankov A, Schwaller J. Potent co-operation between the NUP98–NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction. *Haematologica.* (2014) 99:1465–71. doi: 10.3324/haematol.2013.100917.

75. Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. *Blood.* (2015) 126:943–9. doi: 10.1182/blood-2015-05-567859.

76. Walters DK, Mercher T, Gu TL, O’Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. *Cancer Cell.* (2006) 10:65–75. doi: 10.1016/j.ccr.2006.06.002.

77. Mercher T, Raffel GD, Moore SA, Cornejo MG, Baudry-Bluteau D, Walters DK, et al. Mll-AF4 confers enhanced self-renewal and lymphoid potential and participates in the ontogeny. *Cell Rep.* (2016) 16:1039–54. doi: 10.1016/j.celrep.2016.06.020.

78. Olson LE, Roper RJ, Sengstaken CL, Peterson EA, Aquino V, Galdizki Z, et al. Trisomy for the down syndrome ‘critical region’ is necessary but not sufficient for brain phenotypes of trisomic mice. *Hum Mol Genet.* (2007) 16:7674–82. doi: 10.1093/hmg/ddm022.

79. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, et al. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes bone marrow mesenchymal stem cells from infants with MLL-AF4 positive acute myeloid leukemia induction. *J Clin Invest.* (2015) 133:1415–26. doi: 10.1182/blood-2018-08-835355.

80. Nanda SK, Sondhi A, Dhupia P, Dhupia A, Mohapatra BC, Jhingran A, et al. A murine model of CML blast crisis induced by cooperation between BCR–ABL and NUP98–HOX13. *Blood.* (2009) 119:852–64. doi: 10.1182/blood-2008-07-159501.

81. Rodriguez-Fraticelli AE, Wolock SL, Weinreb CS, Panaro R, Patel SH, Jankovic M, et al. Clonal analysis of lineage fate in native haematopoesis. *Nature.* (2018) 553:212–6. doi: 10.1038/nature25168.

82. Watcham S, Kucinski I, Gottgens B. New insights into hematopoietic differentiation landscapes from single-cell RNA sequencing. *Blood.* (2019) 133:1415–26. doi: 10.1182/blood-2018-08-835355.

83. Nanda SK, Sondhi A, Dhupia P, Dhupia A, Mohapatra BC, Jhingran A, et al. A murine model of CML blast crisis induced by cooperation between BCR–ABL and NUP98–HOX13. *Blood.* (2009) 119:852–64. doi: 10.1182/blood-2008-07-159501.

84. Sanjuan-Pla A, Bueno C, Chen X, Gedman AL, Dang J, et al. Revisiting the biology of infant t(4;11)/MLL-AF4 paradigm and the “co-clinical trial” project. *Cancer Discov.* (2018) 1:108–16. doi: 10.1158/2159-8290.CD-11-0061.
108. de The H, Pandolli PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. (2017) 32:552–60. doi: 10.1016/j.ccell.2017.10.002

109. Lo-Coco F, Arisvasti G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. (2013) 369:11–21. doi: 10.1056/NEJMoa1300874

110. Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. (2012) 7:283–301. doi: 10.1146/annurev-pathol-011811-132434

111. Slany RK. The molecular mechanics of mixed lineage leukemia. Oncogene. (2016) 35:5215–23. doi: 10.1038/onc.2016.30

112. Li R, Wang FG. Modeling and Targeting Pediatric AML. October 2019 | Volume 7 | Article 401

113. Chen CW, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia. Exp Hematol. (2015) 43:673–84. doi: 10.1016/j.exphem.2015.05.012

114. Yokoyama A, Cleary ML. Menin critically links MLL proteins with Trx/MLL and NSL histone-modifying complexes and regulates Hox gene expression. Cell Rep. (2014) 9:433–42. doi: 10.1016/j.celrep.2014.09.002

115. Yokoyama A, Cleary ML. Menin critically links MLL proteins with Trx/MLL and NSL histone-modifying complexes and regulates Hox gene expression. Cell Rep. (2014) 9:433–42. doi: 10.1016/j.celrep.2014.09.002

116. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, et al. The crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem. (2011) 286:31742–8. doi: 10.1074/jbc.M111.258186

117. Murai MJ, Chruszczyk M, Biedrzycka-Romańska N, Wan K, et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature. (2012) 482:542–6. doi: 10.1038/nature10806

118. Borkin D, Klossowski S, Pollock J, Miao H, Linhares BM, Kempinska T, et al. Complexity of blocking bivalent protein–protein interactions: development of a highly potent inhibitor of the menin-mixed-lineage leukemia interaction. J Med Chem. (2016) 61:4832–50. doi: 10.1021/acs.jmedchem.8b00071

119. Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, et al. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in 18(21)-positive leukemic cells. Cancer Res. (2007) 67:2280–9. doi: 10.1182/0008-5472.CAN-06-3360

120. Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with FLT3 mutation: a phase II study. J Invest Med. (2016) 64:424–31. doi: 10.2310/8360.2015.011692

121. Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, et al. A stable molecule inhibitor of the aberrant transcription factor complex nucleated by oligomeric AML1-ETO controls leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science. (2011) 333:765–9. doi: 10.1126/science.1201662

122. Borkin D, Klossowski S, Pollock J, Miao H, Linhares BM, Kempinska T, et al. Pharmacologic inhibition of the Menin–MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. (2015) 27:589–602. doi: 10.1016/j.ccell.2015.02.016

123. Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. (2015) 21:344–52. doi: 10.1038/nm.3830

124. Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, et al. A stable molecule inhibitor of the aberrant transcription factor complex nucleated by oligomeric AML1-ETO controls leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science. (2011) 333:765–9. doi: 10.1126/science.1201662

125. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, et al. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in 18(21)-positive leukemic cells. Cancer Res. (2007) 67:2280–9. doi: 10.1182/0008-5472.CAN-06-3360

126. Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with FLT3 mutation: a phase II study. J Invest Med. (2016) 64:424–31. doi: 10.2310/8360.2015.011692

127. Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, et al. CBFB-SMMHC inhibition triggers apoptosis by disrupting MYC chromatin dynamics in acute myeloid leukemia. Cell. (2018) 174:1325. doi: 10.1016/j.cell.2018.08.014

128. Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, et al. A stable molecule inhibitor of the aberrant transcription factor complex nucleated by oligomeric AML1-ETO controls leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science. (2011) 333:765–9. doi: 10.1126/science.1201662

129. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia. Cancer Cell. (2015) 21:335–43. doi: 10.1016/j.ccr.2015.01.014

130. Yamato G, Yamaguchi H, Handa H, Shiba N, Kawamura M, Wakita S, et al. Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia. Genes Chromosomes Cancer. (2017) 56:800–9. doi: 10.1002/gcc.22483

131. Drake KM, Watson VG, Kiesewelt A, Lynn R, Napper AD. A sensitive luminescent assay for the histone methyltransferase NSD1 and other SAM-dependent enzymes. Assay Drug Dev Technol. (2014) 12:258–71. doi: 10.1089/adt.2014.583

132. Pulikkan JA, Hegde M, Ahmad HM, Belaghzal H, Illendula A, Yu J, et al. CBFB-SMMHC inhibition triggers apoptosis by disrupting MYC chromatin dynamics in acute myeloid leukemia. Cell. (2018) 174:1325. doi: 10.1016/j.cell.2018.08.014

133. Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. (2017) 130:48–58. doi: 10.1182/blood-2016-04-711820
146. Ryan MB, Corcoran RB. Therapeutic strategies to target Ras-mutant cancers. *Nat Rev Clin Oncol.* (2018) 15:709–20. doi: 10.1038/s41571-018-0105-0

147. O’Byrnan JP. Pharmacological targeting of Ras: recent success with direct inhibitors. *Pharmacol Res.* (2019) 139:503–11. doi: 10.1016/j.phrs.2019.10.021

148. Burnett AK, Russell NH, Culligan D, Cavanagh J, Kil J, Wheatley K, et al. Working group of the UK National Cancer Research Institute. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytotoxic does not improve outcome for older patients with AML. *Br J Haematol.* (2012) 158:519–22. doi: 10.1111/j.1365-2414.2012.09165.x

149. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Allotrophic mutant IDH1 inhibitors reveal mechanisms for IDH1 mutant and isoform selectivity. *Structure.* (2017) 25:506–13. doi: 10.1016/j.str.2016.12.017

150. Yen K, Travins J, Wang F, David MD, Artin E, Straley K, et al. AG-221: a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. *Cancer Discov.* (2017) 7:478–93. doi: 10.1158/2159-8290.CD-16-1034

151. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. *N Engl J Med.* (2018) 378:2386–98. doi: 10.1056/NEJMoa1716984

152. Stein EM, DiNardo CD, Fathi AT, Polley DA, Stone RM, Altman JK, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. *Blood.* (2019) 133:667–87. doi: 10.1182/blood-2018-08-869008

153. Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. *Nature.* (2018) 559:125–9. doi: 10.1038/s41586-018-0251-7

154. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013

155. Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. *Cell Death Differ.* (2015) 22:1071–80. doi: 10.1038/cdd.2015.50

156. Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: Blazing the trail for new cancer medicines. *Cancer Discov.* (2018) 8:3879–91. doi: 10.1101/cell.2018.11.004

157. Valentin R, Grabow S, Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. *Blood.* (2018) 132:1248–64. doi: 10.1182/blood-2018-02-791350

158. Pan R, Hogdal LJ, Benito JM, Buccu D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. *Cancer Discov.* (2014) 4:362–75. doi: 10.1158/2159-8290.CD-13-0609

159. Konopleva M, Polley DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. *Cancer Discov.* (2016) 6:1106–17. doi: 10.1158/2159-8290.CD-16-0313

160. Ramsey HE, Fischer MA, Lee T, Gorka AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. *Cancer Discov.* (2018) 8:1566–81. doi: 10.1158/2159-8290.CD-18-0140

161. Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AG-120—a monoclonal antibody against CD33 splicing polymorphism that enables CD33-directed immune therapy for myeloid malignancies. *Cancer Discov.* (2018) 8:1582–97. doi: 10.1158/2159-8290.CD-18-0387

162. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. *Cancer Discov.* (2019) 9:910–25. doi: 10.1158/2159-8290.CD-19-0125

163. Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore I, Morgenstern DA, et al. Accelerating drug development in pediatric cancer: a novel phase I study design of venetoclax in relapsed/refractory malignancies. *Future Oncol.* (2018) 14:2115–29. doi: 10.2217/fon-2018-0121

164. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. AG-120—a monoclonal antibody against CD33 splicing polymorphism that enables CD33-directed immune therapy for myeloid malignancies. *Cancer Discov.* (2018) 8:1582–97. doi: 10.1158/2159-8290.CD-18-0387

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Merchier and Schwaller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.